Inclusion Criteria:  Normal fasting plasma glucose and glycated haemoglobin (HbA1c) <42 mmol/mol Body mass index (BMI) between 18.5 and 25 kg/m2 Haemoglobin >8.3 mmol/l Habitual diet in accordance with the Nordic Nutrition Recommendations Age between 20 and 65 years Oral and written informed consent  Exclusion Criteria:  Diabetes First-degree relatives with diabetes Fasting plasma triacylglycerol indicating dyslipidemia (≥2 mmol/l) Nephropathy (estimated glomerular filtration rate (eGFR) <60 ml/min and/or microalbuminuria with an albumin to creatinine ratio of 30-300 μg/mg) Known liver disease and/or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2 × normal values Signs of liver fibrosis and/or steatosis evaluated by FibroScan (CAP value >2380 dB/m and/or kPa >65.0) and/or FIB-4 score (>1.45) >5% steatosis evaluated by MRI carried out before experimental Day A (see Methods) Use of medication Use of dietary protein supplementation or any other dietary supplements that cannot be paused during participation Excessive training habits, defined as >2 weekly strength and/or aerobic training sessions Pregnancy and/or breastfeeding Implanted metal objects incompatible with magnetic resonance imaging (MRI) Any condition that the investigator feels would interfere with trial completion